Clinical Scenario

Age < 18 years

This protocol covers the acute management of migraine with aura attacks in paediatric patients — those younger than 18 years of age. Drug selection and dosing in children require specific consideration due to age-related safety constraints that differ from adult practice.

First-Line Treatment Approach

The recommended approach centres on weight-adjusted analgesic therapy, with important drug-selection rules that vary according to the child's age. When anti-emetic therapy is required, specific agent guidance applies to this age group.

The full protocol — covering agent selection, weight-based dosing, age-specific thresholds, and anti-emetic criteria — is available via the structured regimen below.

References

DOI: 10.1177/2514183X1882337

Migraine attacks in children are treated with ibuprofen 10 mg/kg body weight (BW), ASA (500 mg) or paracetamol 15 mg/kg BW (second choice).
No Reye Syndrome has yet been observed in children after treatment of migraine with ASA, but the use of ASA is not recommended before the age of 12.
If anti-emetics are necessary, domperidone should be used and not metoclopramide, due to the elevated risk of acute extra-pyramidal dystonia with metoclopramide.

View source ↗

Treatment of Migraine with Aura in Children (Under 18 Years)

References